"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.
In Vivo. 2019 Nov-Dec;33(6):2205-2210. doi: 10.21873/invivo.11723.
BACKGROUND/AIM: Although pelvic exenteration is an aggressive surgical procedure, it remains almost the only curative solution for patients diagnosed with large pelvic malignancies.
We present a series of 100 patients submitted to pelvic exenteration with curative intent.
The origin of the primary tumor was most commonly represented by cervical cancer, followed by, endometrial cancer, rectal cancer, ovarian cancer and vulvo-vaginal cancer. An R0 resection was confirmed in 68 cases, while the remaining 32 cases presented lateral positive resection margins or perineal positive margins. The postoperative morbidity rate was 37% while the mortality rate was 3%. As for the-long term outcomes, the median overall survival time was 38.7 months, being most significantly influenced by the origin of the primary tumor.
Although pelvic exenteration is still associated with an increased morbidity, an important improvement in the long-term survival can be achieved, especially if radical resection is feasible.
背景/目的:尽管盆腔廓清术是一种激进的手术方法,但对于被诊断患有大型盆腔恶性肿瘤的患者来说,它仍然几乎是唯一的治愈方法。
我们报告了一组 100 例接受以治愈为目的的盆腔廓清术的患者。
原发肿瘤的起源最常见的是宫颈癌,其次是子宫内膜癌、直肠癌、卵巢癌和外阴阴道癌。68 例患者的切除标本为 R0 切除,而其余 32 例患者的切除标本为侧方阳性或会阴阳性。术后发病率为 37%,死亡率为 3%。至于长期结果,中位总生存时间为 38.7 个月,主要受原发肿瘤起源的影响。
尽管盆腔廓清术仍与发病率增加相关,但如果可行根治性切除,可显著提高长期生存率。